Chirag Jhaveri, MD
Ophthalmology · Austin, TXNPI 1114117769
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Astellas Pharma US Inc at 40.8% of the total. Reporting peaked in 2024 at $85,525 and has fallen 70.3% since, to $25,390 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 303 payments — averaging $792.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$98K
- Novartis$43K
- Genentech USA, Inc.$28K
- Regeneron Healthcare Solutions, Inc.$23K
- Boehringer Ingelheim International GmbH$18K
- Regeneron$9K
- plus $21K from 18 others
Across 476 payments — averaging $19,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5.4M
- Genentech, Inc.$3M
- Boehringer Ingelheim$429K
- Boehringer Ingelheim International GmbH$114K
- Regeneron$72K
- Sanofi US Services Inc.$60K
- plus $99K from 5 others
What the payments were for
- Consulting fees$96,90440%
- Speaking & faculty fees$121,37851%
- Travel & lodging$14,0156%
- Food & beverage$7,8923%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 62 | $98,010 |
| Novartis | 51 | $43,301 |
| Genentech USA, Inc. | 41 | $27,885 |
| Regeneron Healthcare Solutions, Inc. | 34 | $22,861 |
| Boehringer Ingelheim International GmbH | 33 | $18,445 |
| Regeneron | 8 | $8,836 |
| Boehringer Ingelheim | 4 | $6,371 |
| AbbVie(2 entities) | 20 | $4,641 |
| F. Hoffmann-la Roche AG | 1 | $2,700 |
| Genentech, Inc. | 10 | $2,265 |
| GSK | 1 | $2,220 |
| Alimera Sciences, Inc. | 5 | $1,320 |
| Eyepoint US, Inc. | 7 | $367 |
| Ocular Therapeutix, Inc. | 8 | $307 |
| Biotissue Holdings Inc. | 2 | $205 |
| Optos, Inc. | 2 | $156 |
| Apellis Pharmaceuticals, Inc. | 5 | $139 |
| Harrow Eye, LLC | 2 | $36 |
| Biogen | 2 | $35 |
| Astellas Pharma Global Development | 1 | $30 |
| Alcon | 1 | $30 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $17 |
| Spark Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$93,117
- EYLEA HD$30,941
- SUSVIMO$23,582
- BEOVU$18,414
- VABYSMO$5,771
- BUPARLISIB$4,122
- Lucentis$3,696
- Non-Covered Product$2,925
- OZURDEX$1,500
- Iluvien$1,125
- DEXTENZA$132
- YUTIQ$125
- EYLEA$118
- Prokera$106
- AmnioGraft$106
- AmnioGuard$106
How this compares
$240,209 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 133 | $5,515 |
| Brinzolamide | 13 | $1,844 |
| Difluprednate | 22 | $1,691 |
| Latanoprost | 77 | $1,073 |
| Ofloxacin | 55 | $832 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 48 | $649 |
| Ketorolac Tromethamine | 18 | $549 |
| Ciprofloxacin Hcl | 19 | $193 |
| Brimonidine Tartrate | 11 | $34 |
| Timolol Maleate | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Austin
- Sheila BarbarinoAustin$232K
- Aaron RollerAustin$202K
- Philip StoreyAustin$161K
- Robert WongAustin$113K
- Farhan IrshadAustin$111K
- Edward WoodAustin$110K
- Ryan YoungAustin$105K
- Steven DellAustin$94K
- Shelley GhafooriAustin$73K
- Michael SingerSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.